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TO THE EDITOR
The relative contribution of erythroid,
dermal, and hepatic ferrochelatase
(FECH) genotype and enzyme defi-
ciency to dermal photosensitivity and
liver disease in erythropoietic protopor-
phyria (EPP) is not entirely elucidated.
A better understanding is critical when
treatment options are discussed.
A previous publication in the Journal
of Investigative Dermatology (Pawliuk
et al., 2005) highlighted these issues
and elicited subsequent contributions to
the discussion (Elder, 2005; Leboulche
and Mathews-Roth, 2005; Lim, 2005).
Pawliuk et al. (2005) transplanted bone
marrow from an EPP mouse model to
normal recipients. Despite elevated
protoporphyrin levels, the recipients
did not develop cutaneous photosensi-
tivity or liver disease. In a second
experiment, photosensitivity did not
develop in skin transplanted from nor-
mal mice to EPP mice. The authors
suggested that elevated protoporphyrin
levels alone are insufficient to generate
photosensitivity or liver disease in EPP,
and that restoration of dermal FECH
activity should potentially minimize
photosensitivity.
The conclusions drawn from the
mouse model do not seem to apply to
human EPP. The accumulated experience
from different clinical situations, including
organ transplantation in humans, points to
differences between EPP in mice and
humans, and may enable some prelimin-
ary conclusions to be drawn.
In mice, an elevated protoporphyrin
level after transplanting EPP marrow
into healthy mice is insufficient to
generate photosensitivity (Pawliuk
et al., 2005) and does not cause liver
disease (Fontanellas et al., 2000). A
corresponding human situation would
be adult onset EPP caused by acquired
somatic FECH mutations associated
with myelodysplastic syndrome. Sev-
eral reports (Sassa et al., 2002) have
described cases with elevated proto-
porphyrin levels, severe photosensitiv-
ity, and even protoporphyric liver
disease (Goodwin et al., 2006) despite
normal genotype and FECH activity
outside the marrow.
The experiment with transplantation
of normal skin to EPP mice suggested
that restoration of dermal FECH activity
could prevent photosensitivity. This
cannot be refuted by referring to ex-
perience in human EPP. Two other
examples might be considered corre-
sponding human situations, in which
dermal cells with normal FECH geno-
type have to handle excess protopor-
phyrin. In photodynamic therapy, proto
porphyrin is accumulated after topical
administration of aminolevulinic acid
despite normal FECH activity (Krammer
and Plaetzer, 2008). The subsequent
local photosensitivity forms the basis for
photodynamic therapy. In the recently
described new form of porphyria,
x-linked dominant protoporphyria
(Whatley et al., 2008), protoporphyrin
accumulates as ferrochelatase cannot
keep up with an increased protoporphyrin
load despite normal FECH activity.
Whether cellular protoporphyrin levels in
these different situations are comparable
has never been studied. It still seems
unlikely that mere restoration of dermal
FECH activity would suffice to prevent
photosensitivity in EPP if the protopor-
phyrin load remains high.
The fact that hematopoietic stem cell
transplantation (HSCT) does not entirely
normalize circulating protoporphyrin
levels or reverse liver damage in mice
(Fontanellas et al., 2000), indicate that
the mouse model has a larger propor-
tion of circulating protoporphyrin of
non-erythroid origin, although strains
may be heterogeneous (Abitbol et al.,
2005). Among the few human cases
that have been treated by HSCT,
porphyrin levels were completely nor-
malized, which cured photosensitivity
and prevented recurrence of liver
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disease (Rand et al., 2006), even when
HSCT was done without a preceding
liver transplantation (Wahlin et al.,
2007). At least 80% of the excess
protoporphyrin has erythroid origin in
human EPP (Bloomer et al., 1991).
Earlier studies have suggested that the
liver might contribute significantly in
some individuals (Lamon et al., 1980),
but the evidence is not very strong.
Liver transplantation has been per-
formed in many EPP patients with end-
stage liver disease. Photosensitivity,
although absent in some patients initi-
ally (Mion et al., 1992; Leone et al.,
2000), remains after transplantation
(McGuire et al., 2005). Recurrent graft
disease occurred in 75% of patients
after 7 years in the American cohort of
20 cases (McGuire et al., 2005).
Gene therapy on hematopoietic cells
cured photosensitivity in mice (Pawliuk
et al., 1999; Fontanellas et al., 2001),
but has not been attempted in man. The
high frequency of graft disease recur-
rence after liver transplantation also
argues against the feasibility of liver-
directed gene therapy to prevent or cure
significant liver disease in human EPP.
In our previously reported case
(Wahlin et al., 2007), HSCT as mono-
therapy cured all phenotypic signs of
EPP. Liver biochemistry and porphyrin
biochemistry in blood, urine, and feces
have remained normal for more than 3
years that have now passed since
HSCT. The FECH genotype is normal
in peripheral blood cells, but the
dermal genotype remains the same as
before HSCT (Figure 1). The patient has
taken several trips to Mediterranean
beach resorts, spending long days in
the sun without experiencing any
photosensitivity.
The understanding of the partially
unresolved questions regarding the rela-
tive importance of erythroid, hepatic, and
dermal FECH activity in human EPP has
grown. It confirms what we thought we
knew before the studies on mice were
published. Although the experience may
still be limited, these findings strengthen
the concept of the bone marrow as the
main source of protoporphyrin excess in
human EPP. There is no clear evidence
that the hepatocyte FECH deficiency is
clinically relevant by itself, that dermal
FECH deficiency is sufficient to cause
photosensitivity, or that normalized
FECH activity would cure photosensitiv-
ity in human EPP. The EPP mice models
thus differ significantly from human EPP.
Effective treatments to prevent
and treat cutaneous photosensitivity
need to be devised. HSCT is the only
curative option in human EPP, but is
presently an option only for patients
with protoporphyric liver disease (Wah-
lin and Harper, 2009). The mechanisms
and determinants of liver injury caused
by protoporphyrin remain elusive, but
need to be delineated if patients suita-
ble for curative HSCT are to be
identified early, before the liver fails.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Maire Kotaja¨rvi for her dedicated work
with the mutation analyses.
Staffan Wahlin1 and Pauline Harper2
1Department of Gastroenterology and
Hepatology, Karolinska Institutet, Karolinska
University Hospital, Stockholm, Sweden and
2Department of Laboratory Medicine,
Porphyria Centre Sweden, Karolinska Institutet,
Karolinska University Hospital, Stockholm,
Sweden
E-mail: staffan.wahlin@karolinska.se
REFERENCES
Abitbol M, Bernex F, Puy H, Jouault H, Deybach
JC, Guenet JL et al. (2005) A mouse model
provides evidence that genetic background
modulates anemia and liver injury in ery-
thropoietic protoporphyria. Am J Physiol
Gastrointest Liver Physiol 288:G1208–16
Bloomer JR, Hill HD, Kools AM, Straka JG (1991)
Heme synthesis in protoporphyria. Curr Probl
Dermatol 20:135–47
Elder G (2005) Normal dermal ferrochelatase
activity does not protect human skin from proto-
porphyrin-induced photosensitivity. J Invest
Dermatol 125:580–1 (author reply 580—581)
Fontanellas A, Mazurier F, Landry M, Taine L,
Morel C, Larou M et al. (2000) Reversion of
hepatobiliary alterations by bone marrow
transplantation in a murine model of erythro-
poietic protoporphyria. Hepatology 32:73–81
Fontanellas A, Mendez M, Mazurier F, Cario-
Andre M, Navarro S, Ged C et al. (2001)
Successful therapeutic effect in a mouse
model of erythropoietic protoporphyria by
partial genetic correction and fluorescence-
based selection of hematopoietic cells. Gene
Ther 8:618–26
Goodwin RG, Kell WJ, Laidler P, Long CC,
Whatley SD, McKinley M et al. (2006)
Photosensitivity and acute liver injury in
myeloproliferative disorder secondary to
late-onset protoporphyria caused by deletion
of a ferrochelatase gene in hematopoietic
cells. Blood 107:60–2
Krammer B, Plaetzer K (2008) ALA and its clinical
impact, from bench to bedside. Photochem
Photobiol Sci 7:283–9
Lamon JM, Poh-Fitzpatrick MB, Lamola AA (1980)
Hepatic protoporphyrin production in human
protoporphyria. Effects of intravenous hema-
tin and analysis of erythrocyte protoporphyr-
in distribution. Gastroenterology 79:115–25
1 2 3 4 5 6 7
1 2 3 4 5 6 7
Figure 1. Ferrochelatase genotype in blood and dermal fibroblasts. (a) Denaturing gradient gel
electrophoresis. Lane 1, the null-allele mutation, 930G4A, in the FECH gene in blood before HSCT.
Lane 2, the null-allele mutation, 930G4A, in the FECH gene in blood after HSCT. Lane 3, the null-allele
mutation, 930G4A, in the FECH gene in blood at present. Lane 4, the 930G4A mutation in dermal
fibroblasts at present. Lane 5, normal control. Lane 6, 930G4T control. Lane 7, 921G/A control.
(b) Restriction enzyme cleavage analysis. Lane 1, polymorphic locus, IVS3-48 (C/T), in intron 3 in blood
before HSCT. Lane 2, polymorphic locus, IVS3-48 (C/T), in intron 3 in blood after HSCT. Lane 3,
polymorphic locus, IVS3-48 (C/T), in intron 3 in blood at present. Lane 4, polymorphic locus, IVS3-48
(C/T), in intron 3 in dermal fibroblasts at present. Lanes 5–7, control C/T, T/T, and C/C.
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